{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T08:48:02Z","timestamp":1785746882800,"version":"3.56.0"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>Cardiovascular disease (CVD) is a major long-term complication in cancer survivors treated with chemotherapy, yet risk varies markedly across individuals. Using the UK Biobank, we studied chemotherapy-treated cancer patients without baseline CVD and identified data-driven cardio-oncology risk phenotypes with unsupervised clustering (UMAP embedding and HDBSCAN). We evaluated associations between phenotypes and incident CVD using Cox proportional hazards models and assessed 5-year risk discrimination with and without phenotype labels. Among 18,693 patients, 9 stable phenotypes were identified, characterized by distinct patterns of cancer treatment exposure, baseline cardiovascular medication use, cardiometabolic burden, renal function, and lifestyle factors. Compared with the reference phenotype, all phenotypes had higher risks of composite CVD, and the highest-risk phenotype demonstrated a hazard ratio of 4.06 (95% CI, 3.44\u20134.78). Phenotype-defining features were interpreted using SHAP values. In subtype analyses, heterogeneity was most apparent for ischemic heart disease, angina pectoris, and acute myocardial infarction. Adding phenotype labels modestly improved 10-year discrimination, with AUC values increasing from 0.648 to 0.692. These findings suggest that phenotype-based profiling may provide an exploratory framework for risk stratification in cardio-oncology and may help characterize risk heterogeneity across cancer survivors treated with chemotherapy.<\/jats:p>","DOI":"10.3389\/fcvm.2026.1826258","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T08:27:10Z","timestamp":1785745630000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Cardio-Oncology Risk Phenotypes in Cancer Patients Treated with Chemotherapy: A Data-Driven Analysis"],"prefix":"10.3389","volume":"13","author":[{"given":"Xiaolin","family":"Gao","sequence":"first","affiliation":[{"name":"Department of Anesthesiology, The Second Clinical College of Guangzhou Medical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kexin","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, The Nanshan Clinical College of Guangzhou Medical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haowen","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, The Third Clinical College of Guangzhou Medical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andong","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, The Second Clinical College of Guangzhou Medical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiexinhao","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, The Nanshan Clinical College of Guangzhou Medical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianpeng","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, The Second Clinical Medical College, Southern Medical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiutong","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, The Sixth Clinical College of Guangzhou Medical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruilang","family":"Zhong","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, The First Clinical College of Guangzhou Medical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, The Third Clinical College of Guangzhou Medical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruirui","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, The Second Clinical Medical College, Southern Medical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weipeng","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Orthopaedics, School of Medicine, The Second Affiliated Hospital of South China University of Technology (Guangzhou First People's Hospital)","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenie","family":"Wang","sequence":"additional","affiliation":[{"name":"Shengli Clinical Medical College of Fujian Medical University, Department of Breast Surgery, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, The Second Affiliated Hospital, School of Medicine, The Chinese University of Hong Kong, Shenzhen & Longgang District People's Hospital of Shenzhen","place":["Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, The Second Affiliated Hospital, School of Medicine, The Chinese University of Hong Kong, Shenzhen & Longgang District People's Hospital of Shenzhen","place":["Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1001\/jamaoncol.2024.5381","article-title":"Estimation of cancer deaths averted from prevention, screening, and treatment efforts, 1975\u20132020","volume":"11","author":"Goddard","year":"2025","journal-title":"JAMA Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jacc.2022.04.042","article-title":"Cardiovascular disease risk among cancer survivors: the atherosclerosis risk in communities (ARIC) study","volume":"80","author":"Florido","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.jare.2024.12.039","article-title":"Risk classification for non-cancer death in middle-aged cancer patients","volume":"76","author":"Guan","year":"2025","journal-title":"J Adv Res"},{"key":"B5","doi-asserted-by":"publisher","first-page":"afad068","DOI":"10.1093\/ageing\/afad068","article-title":"Long-term risks of cardiovascular death in a population-based cohort of 1,141,675 older patients with cancer","volume":"52","author":"Guan","year":"2023","journal-title":"Age Ageing"},{"key":"B6","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1093\/eurheartj\/ehaa779","article-title":"Long-term cardiovascular disease mortality among 160 834 5-year survivors of adolescent and young adult cancer: an American population-based cohort study","volume":"42","author":"Wang","year":"2021","journal-title":"Eur Heart J"},{"key":"B7","doi-asserted-by":"publisher","first-page":"3102","DOI":"10.1002\/cncr.32885","article-title":"Long-term causes of death among pediatric patients with cancer","volume":"126","author":"Horn","year":"2020","journal-title":"Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jaccao.2022.01.102","article-title":"Does cardiovascular mortality overtake cancer mortality during cancer survivorship?: an English retrospective cohort study","volume":"4","author":"Strongman","year":"2022","journal-title":"JACC CardioOncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.jare.2024.03.017","article-title":"Long-term and short-term cardiovascular disease mortality among patients of 21 non-metastatic cancers","volume":"69","author":"Guan","year":"2025","journal-title":"J Adv Res"},{"key":"B10","doi-asserted-by":"publisher","first-page":"760","DOI":"10.7150\/ijbs.65258","article-title":"Underlying the mechanisms of doxorubicin-induced acute cardiotoxicity: oxidative stress and cell death","volume":"18","author":"Kong","year":"2022","journal-title":"Int J Biol Sci"},{"key":"B11","doi-asserted-by":"publisher","first-page":"797","DOI":"10.3390\/ijms19030797","article-title":"Chemotherapeutic-induced cardiovascular dysfunction: physiological effects, early detection-the role of telomerase to counteract mitochondrial defects and oxidative stress","volume":"19","author":"Quryshi","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B12","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12964-023-01077-5","article-title":"Role of oxidative stress and inflammation-related signaling pathways in doxorubicin-induced cardiomyopathy","volume":"21","author":"Shi","year":"2023","journal-title":"Cell Commun Signal"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1161\/circresaha.115.303633","article-title":"Cardio-oncology: an update on cardiotoxicity of cancer-related treatment","volume":"118","author":"Lenneman","year":"2016","journal-title":"Circ Res"},{"key":"B14","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"B15","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/jnci\/djp440","article-title":"Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention","volume":"102","author":"Albini","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1093\/jnci\/djae107","article-title":"Long-term cardiovascular disease risk after anthracycline and trastuzumab treatments in US breast cancer survivors","volume":"116","author":"Vo","year":"2024","journal-title":"J Natl Cancer Inst"},{"key":"B17","doi-asserted-by":"publisher","first-page":"4138","DOI":"10.1002\/cncr.35503","article-title":"Cardiovascular disease and stroke following cancer and cancer treatment in older adults","volume":"130","author":"Muhandiramge","year":"2024","journal-title":"Cancer"},{"key":"B18","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.jaccao.2024.07.016","article-title":"Anthracycline cardiotoxicity in adult cancer patients: JACC: CardioOncology state-of-the-art review","volume":"6","author":"Camilli","year":"2024","journal-title":"JACC CardioOncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1186\/s12967-024-05537-5","article-title":"Genetic factors in the pathogenesis of cardio-oncology","volume":"22","author":"Qi","year":"2024","journal-title":"J Transl Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e1406","DOI":"10.1016\/s2214-109x(25)00155-x","article-title":"The burden of cardiovascular events according to cardiovascular risk profile in adults from high-income, middle-income, and low-income countries (PURE): a cohort study","volume":"13","author":"Leong","year":"2025","journal-title":"Lancet Glob Health"},{"key":"B21","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1002\/ejhf.1621","article-title":"Phenomapping of patients with heart failure with preserved ejection fraction using machine learning-based unsupervised cluster analysis","volume":"22","author":"Segar","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e0000334","DOI":"10.1371\/journal.pdig.0000334","article-title":"A population-based study exploring phenotypic clusters and clinical outcomes in stroke using unsupervised machine learning approach","volume":"2","author":"Akyea","year":"2023","journal-title":"PLOS Digit Health"},{"key":"B23","doi-asserted-by":"publisher","first-page":"204","DOI":"10.2337\/dc20-2806","article-title":"Cluster analysis of cardiovascular phenotypes in patients with type 2 diabetes and established atherosclerotic cardiovascular disease: a potential approach to precision medicine","volume":"45","author":"Sharma","year":"2022","journal-title":"Diabetes Care"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/s0140-6736(12)60404-8","article-title":"What makes UK biobank special?","volume":"379","author":"Collins","year":"2012","journal-title":"Lancet"},{"key":"B25","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"B26","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/s0140-6736(09)61717-7","article-title":"C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis","volume":"375","author":"Kaptoge","year":"2010","journal-title":"Lancet"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e333","DOI":"10.1093\/ehjci\/jeac106","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"23","author":"Lyon","year":"2022","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1093\/eurheartj\/ehab309","article-title":"SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe","volume":"42","year":"2021","journal-title":"Eur Heart J"},{"key":"B29","doi-asserted-by":"publisher","first-page":"j2099","DOI":"10.1136\/bmj.j2099","article-title":"Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study","volume":"357","author":"Hippisley-Cox","year":"2017","journal-title":"Br Med J"},{"key":"B30","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1161\/01.cir.0000437741.48606.98","article-title":"2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology\/American Heart Association task force on practice guidelines","volume":"129","author":"Goff","year":"2014","journal-title":"Circulation"},{"key":"B31","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1111\/bjh.15603","article-title":"Cumulative anthracycline exposure and risk of cardiotoxicity; a Danish nationwide cohort study of 2440 lymphoma patients treated with or without anthracyclines","volume":"183","author":"Baech","year":"2018","journal-title":"Br J Haematol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaccao.2024.06.006","article-title":"Cardiovascular considerations after cancer therapy: gaps in evidence and JACC: CardioOncology expert panel recommendations","volume":"7","author":"Blaes","year":"2025","journal-title":"JACC CardioOncol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"e24269","DOI":"10.1002\/clc.24269","article-title":"Incidence of chemotherapy-related cardiac dysfunction in cancer patients","volume":"47","author":"Deng","year":"2024","journal-title":"Clin Cardiol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"477","DOI":"10.3322\/caac.21863","article-title":"Breast cancer statistics 2024","volume":"74","author":"Giaquinto","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B35","doi-asserted-by":"publisher","first-page":"3837","DOI":"10.1007\/s12094-025-03894-1","article-title":"Sex and gender differences in cancer pathogenesis and pharmacology","volume":"27","author":"Bernardez","year":"2025","journal-title":"Clin Transl Oncol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.1038\/s41467-024-46945-x","article-title":"Outcome differences by sex in oncology clinical trials","volume":"15","author":"Kammula","year":"2024","journal-title":"Nat Commun"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1002\/ejhf.1920","article-title":"Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society","volume":"22","author":"Lyon","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1001\/jama.2009.1619","article-title":"Major lipids, apolipoproteins, and risk of vascular disease","volume":"302","author":"Di Angelantonio","year":"2009","journal-title":"JAMA"},{"key":"B39","doi-asserted-by":"publisher","first-page":"e2442639","DOI":"10.1001\/jamanetworkopen.2024.42639","article-title":"Smoking cessation and incident cardiovascular disease","volume":"7","author":"Cho","year":"2024","journal-title":"JAMA Netw Open"},{"key":"B40","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","article-title":"2024 ESC guidelines for the management of elevated blood pressure and hypertension","volume":"45","author":"McEvoy","year":"2024","journal-title":"Eur Heart J"},{"key":"B41","doi-asserted-by":"publisher","first-page":"103274","DOI":"10.1016\/j.eclinm.2025.103274","article-title":"Risk of cardiovascular disease among cancer survivors: systematic review and meta-analysis","volume":"84","author":"Li","year":"2025","journal-title":"EClinicalMed"},{"key":"B42","doi-asserted-by":"publisher","first-page":"e009707","DOI":"10.1161\/circimaging.119.009707","article-title":"Unsupervised cluster analysis of patients with aortic stenosis reveals distinct population with different phenotypes and outcomes","volume":"13","author":"Kwak","year":"2020","journal-title":"Circ Cardiovasc Imaging"},{"key":"B43","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1001\/jama.2009.943","article-title":"Novel and conventional biomarkers for prediction of incident cardiovascular events in the community","volume":"302","author":"Melander","year":"2009","journal-title":"Jama"},{"key":"B44","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1161\/circulationaha.106.672402","article-title":"Use and misuse of the receiver operating characteristic curve in risk prediction","volume":"115","author":"Cook","year":"2007","journal-title":"Circulation"},{"key":"B45","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1001\/jama.2019.22241","article-title":"Predictive accuracy of a polygenic risk score-enhanced prediction model vs a clinical risk score for coronary artery disease","volume":"323","author":"Elliott","year":"2020","journal-title":"Jama"},{"key":"B46","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1161\/circulationaha.114.010637","article-title":"Phenomapping for novel classification of heart failure with preserved ejection fraction","volume":"131","author":"Shah","year":"2015","journal-title":"Circulation"},{"key":"B47","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1038\/s41591-024-03299-7","article-title":"Subclassification of obesity for precision prediction of cardiometabolic diseases","volume":"31","author":"Coral","year":"2025","journal-title":"Nat Med"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1826258\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T08:27:11Z","timestamp":1785745631000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1826258\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,3]]},"references-count":47,"alternative-id":["10.3389\/fcvm.2026.1826258"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1826258","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,3]]},"article-number":"1826258"}}